Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Equity Ratio (2023 - 2025)

Kura Oncology (KURA) has disclosed Equity Ratio for 3 consecutive years, with 0.24 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 56.66% to 0.24 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.24, a 56.66% decrease, with the full-year FY2025 number at 0.24, down 56.66% from a year prior.
  • Equity Ratio was 0.24 for Q4 2025 at Kura Oncology, down from 0.37 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.93 in Q2 2023 to a low of 0.24 in Q4 2025.
  • A 3-year average of 0.7 and a median of 0.88 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: fell 1.71% in 2024, then plummeted 57.8% in 2025.
  • Kura Oncology's Equity Ratio stood at 0.88 in 2023, then tumbled by 38.51% to 0.54 in 2024, then tumbled by 56.66% to 0.24 in 2025.
  • Per Business Quant, the three most recent readings for KURA's Equity Ratio are 0.24 (Q4 2025), 0.37 (Q3 2025), and 0.45 (Q2 2025).